Mirum Pharmaceuticals Inc. has announced its financial results for the first quarter of 2025, reporting total revenues of $111.6 million. This marks a significant increase from the $69.2 million reported for the same period in 2024. The company has also raised its full-year revenue guidance to a range of $435 million to $450 million. The first quarter global net product sales were $111.6 million, with LIVMARLI net product sales amounting to $73.2 million, reflecting a 71% growth over the first quarter of 2024. Additionally, Bile Acid Medicines net product sales reached $38.4 million, showing a 47% increase from the previous year. Total operating expenses for the quarter were $126.8 million, up from $95.7 million in the first quarter of 2024. Included in these expenses were $21.9 million in non-cash stock-based compensation, intangible amortization, and other non-cash expenses compared to $17.1 million for the same quarter last year. As of March 31, 2025, Mirum's unrestricted cash, cash equivalents, and investments stood at $298.6 million, slightly up from $292.8 million at the end of 2024. On the business operations front, Mirum has achieved several milestones, including the FDA's approval of the LIVMARLI oral tablet formulation. The company is also progressing with its VISTAS study of volixibat in primary sclerosing cholangitis $(PSC.AU)$, expecting to complete enrollment in the third quarter of 2025, with topline data anticipated in the second quarter of 2026. Additionally, the LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions is expected to complete enrollment in 2026, and a Phase 2 study for MRM-3379 in Fragile X Syndrome is set to begin in 2025.